Clinical Trials Logo

Dry Eye Syndromes clinical trials

View clinical trials related to Dry Eye Syndromes.

Filter by:

NCT ID: NCT04674358 Completed - Dry Eye Clinical Trials

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Start date: November 21, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.

NCT ID: NCT04670263 Completed - Dry Eye Disease Clinical Trials

Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)

Start date: March 8, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Dry Eye disease signs and symptoms are reduced in patients who receive topical steroids and topical hyaluronic acid. AdOM's Tear Film Imager measurements are reproducible and it can diagnose the dry eye disease state in a single, non-invasive measurement. The Tear Film Imager can provide objective accurate measurements of the dry eye treatment effectiveness.

NCT ID: NCT04669561 Completed - Dry Eye Clinical Trials

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

CLEAR
Start date: March 17, 2021
Phase: Phase 4
Study type: Interventional

In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.

NCT ID: NCT04668131 Completed - Dry Eye Clinical Trials

Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease

Start date: September 22, 2020
Phase: N/A
Study type: Interventional

This project is designed as a prospective, randomized, open, controlled clinical trial. For the first time, acupuncture was applied to the treatment of dry ocular neuropathic pain. Its mechanism was discussed by comparing the efficacy between acupuncture and artificial tears.

NCT ID: NCT04663529 Completed - Dry Eye Clinical Trials

Correlation Study of Corneal Nerve Changes and Dry Eye in Contact Lens Wearers

Start date: October 1, 2020
Phase:
Study type: Observational

This study aims to analyze the changes of corneal nerve morphology and function in contact lens-related dry eye(CLADE) patients and further discuss the role of corneal nerve in the genesis and development of CLADE.

NCT ID: NCT04658927 Completed - Clinical trials for Meibomian Gland Dysfunction

Dextenza With ILUX for Treatment of MGD

Start date: January 4, 2021
Phase: Phase 4
Study type: Interventional

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing iLUX MGD Treatment System.

NCT ID: NCT04656197 Completed - Dry Eye Disease Clinical Trials

The Ocular Microbiome in Patients With Dry Eye Disease

Start date: September 30, 2019
Phase:
Study type: Observational

The primary objective of this study is the characterization of the ocular microbiome in a healthy cohort and in patients with dry eye disease using whole-metagenome shotgun sequencing. Secondary objectives are the identification of differences between the ocular microbiome of healthy controls and patients with dry eye disease as well as between the ocular and the gut microbiome.

NCT ID: NCT04649177 Completed - Dry Eye Syndromes Clinical Trials

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

Start date: December 15, 2020
Phase: N/A
Study type: Interventional

EYEdeal Scanning Technology enables rapid measurement of corneal and scleral topography. By accurately measuring the ocular surface with this imaging technology, the current iterative fitting method required to fit PROSE (prosthetic replacement of the ocular surface ecosystem) devices could be replaced and/or strengthened with a more rapid, automated fitting sequence. This could considerably reduce the time needed per visit, the number of visits, and the number of devices needed to be manufactured to reach the endpoint. Additionally, the scanning technology may afford the opportunity to successfully fit some pathology that were previously treatment failures. The automated technology may as well reduce the intensive clinician training time needed to fit PROSE devices, therefore increasing the availability and access to patients. The goal of this research is to evaluate the reliability and efficacy of this automated technology for fitting PROSE devices. Data from real-time measurement of the human eye ocular surface topography will be used to fabricate a prosthetic lens. The fit of the PROSE device will be evaluated, as well as the subjective comfort of the fit.

NCT ID: NCT04648085 Completed - Dry Eye Clinical Trials

Effect of Trigeminal Nerve Stimulation on Corneal Nerves and Chronic Ocular Pain

Start date: February 3, 2021
Phase: N/A
Study type: Interventional

Individuals with dry eye tend to present with ocular pain which persists despite the use of topical treatment. This could be secondary to somatosensory impairment attributable to neuropathic pain. The purpose of this study is to evaluate the effect of trigeminal nerve stimulation (TNS) on corneal nerves and chronic ocular pain in patients with dry eye.

NCT ID: NCT04645446 Completed - Dry Eye Disease Clinical Trials

Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome

ProGIFT
Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 clinical trial. The study objective is to evaluate the safety and efficacy of two different concentrations (0.5% and 1%) of progesterone topical gel compared to placebo, when administered twice a day for 3 months (12 weeks) in patients diagnosed with moderate to severe dry eye syndrome.